HURA · TuHURA Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| James A. Bianco Chief Executive Officer | ▼ Sell | Gift | 2,173,307 Shares held | 5/28/2026 | View profile |
| Anthony Scott Praill Chief Financial Officer | ▲ Buy | Grant | 277,273 Shares held | 8/1/2022 | View profile |
| Robert E. Hoffman President and CEO | ▲ Buy | Grant | 68,902 Shares held | 6/1/2023 | View profile |
| Saiid Zarrabian Head of Strategic Partnerships | ▲ Buy | Open Market | 55,500 Shares held | 12/7/2021 | View profile |
| Dennis M. Brown Chief Scientific Officer | ▼ Sell | Other | 5,302 Shares held | 1/5/2023 | View profile |
| Laura L. Johnson Director | ▲ Buy | Open Market | 3,000 Shares held | 11/22/2021 | View profile |
Transaction History
| James A. Bianco | ▼ Sell | Gift | 150,000 | $0 | 5/28/2026 |
| James A. Bianco | ▲ Buy | Grant | 2,323,307 | $0 | 10/18/2024 |
| Robert E. Hoffman | ▲ Buy | Grant | 59,800 | $0 | 6/1/2023 |
| Dennis M. Brown | ▼ Sell | Other | 363 | $0 | 1/5/2023 |
| Anthony Scott Praill | ▲ Buy | Grant | 240,087 | $0 | 8/1/2022 |
| Dennis M. Brown | ▲ Buy | Grant | 240,087 | $0 | 8/1/2022 |
| Robert E. Hoffman | ▲ Buy | Grant | 400,145 | $0 | 8/1/2022 |
| Robert E. Hoffman | ▲ Buy | Open Market | 55,000 | $26K | 2/15/2022 |
| Anthony Scott Praill | ▲ Buy | Open Market | 28,700 | $19K | 12/8/2021 |
| Saiid Zarrabian | ▲ Buy | Open Market | 38,109 | $24K | 12/7/2021 |
| Saiid Zarrabian | ▲ Buy | Open Market | 11,891 | $7K | 12/6/2021 |
| Laura L. Johnson | ▲ Buy | Open Market | 3,000 | $2K | 11/22/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HURA Secures U.S. Patent for DOR Antagonist Delivery
TuHURA Biosciences has been granted a U.S. patent covering the administration of DOR antagonists. The approval protects the company’s delivery technology and could support future drug development or licensing deals. The patent may strengthen HURA’s intellectual property portfolio and provide a competitive edge in the field of opioid receptor research.
HURA Secures U.S. Patent for DOR Antagonist Delivery. TuHURA Biosciences has been granted a U.S. patent covering the administration of DOR antagonists. The approval protects the company’s delivery technology and could support future drug development or licensing deals. The patent may strengthen HURA’s intellectual property portfolio and provide a competitive edge in the field of opioid receptor research.